Market Research Blog

[300 Pages Report] The global HIV antivirals market is expected to be worth $30.6 billion in 2022, with a CAGR of 4.4 percent during the forecast period (2022-2032). According to a recent study, fixed-dose combinations (FDCs) will account for more than 83 percent of the HIV antivirals market in 2021.

According to Future Market Insights, the global HIV antivirals market was around US$ 29.4 Bn in 2021 and is expected to exhibit a CAGR of close to 4.4% over the forecast period (2022-2032).

The demand for HIV antivirals is increasing due to growing prevalence of HIV across the globe. For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS), approximately 37.7 million people were infected with HIV in the world in 2020.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15095

Market Outlook:

Data Points	Market Insights
HIV Antivirals Market Value 2021dg	US$ 29.4 Bn
Market Value 2022	US$ 30.6 Bn
Market Value 2032	US$ 47.0 Bn
CAGR 2022-2032	4.4%
Market Share of Top 5 Countries	64.8%

Further, demand for HIV antivirals will also surge amid surging rate of unprotected sex and the use of contaminated needles or syringes. As per the National Youth Risk Behavior Survey provided by the Centers for Disease Control and Prevention (CDC), 38% of the respondents had sexual intercourse, and 9% had four or more sexual partners in the U.S., during high school, in 2019.

Hence, key players are developing generic anti-HIV drugs at cost-effective prices to capitalize on growing demand. For instance, generic versions of Lamivudine, Abacavir, and Efavirenz are available in the U.S. at prices lower than their branded versions. This is expected to create lucrative opportunity for the generic HIV antivirals manufacturers to provide affordable medical facilities in low and middle-income countries.

Key Takeaways from Market Study

• Fixed-dose combinations (FDCs) segment held over 83.2% market value share in 2021, owing to their ability to improve adherence to an HIV treatment regimen.
• Hospital pharmacies are the leading sales channel of the HIV antivirals, with over 53% of the market share in 2021, and are anticipated to grow at a CAGR rate of 4. 5% in upcoming decade
• North America is expected to dominate the global HIV antivirals market, holding a share of 38.7% in 2021.
• India is expected to lead the growth in South Asia market owing to the growing cases of HIV in the country

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-15095

“With increasing awareness among the people about HIV causes and symptoms, the HIV antivirals market is set witness positive growth during the forecast period. Hence, key players are developing anti-HIC drugs vaccines to increase their revenue,” says an analyst of Future Market Insights.

Market Competition

Market players are expanding the business through collaborations, and increasing involvement in clinical trials as the key strategy with instances of key companies, such as Merck and Gilead, in order to improve their reach in the market and compete with other key players in forthcoming years. For instance:

• In October 2021, Merck announced favorable results from two pivotal Phase 3 trials of the investigational, once-daily oral fixed-dose combination pill of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection.
• In March 2021, Gilead announced the development and commercialization of long-acting, investigational treatment combinations of Lenacapavir and Islatravir in HIV in association with Merck.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the HIV antiviral market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research study is based on the product – (fixed-dose combinations (FDCs), integrase strand transfer inhibitors (INSTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry inhibitors – CCR5 co-receptor antagonist, protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), and others), by sales channel (hospital pharmacies, retail pharmacies, and online pharmacies) across seven key regions of the world.

For in-depth insights, Download a PDF Brochure@ https://www.futuremarketinsights.com/reports/brochure/rep-gb-15095

Key Players :

• ViiV Healthcare
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Johnson & Johnson
• Genetech, Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie
• Cipla
• Pfizer Inc.
• Mylan N.V.
• Bristol-Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Macleods Pharmaceuticals Ltd
• Emcure Pharmaceuticals Limited
• Aspen Pharmacare Limited
• Lupin Ltd.
• Sun Pharmaceutical Industries Ltd.
• Theratechnologies Inc.
• Strides Arcolab Limited
• Hetero labs limited
• Laurus Laboratories Ltd

Key Market Segments Covered in HIV Antivirals Market Research

By Product:

• Fixed Dose Combinations (FDCs)
• Integrase Strand Transfer Inhibitors (INSTIs)
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Entry Inhibitors – CCR5 co-receptor antagonist
• Protease Inhibitors (PIs)
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

As per Future Market Insights’ latest analysis, the global hemostatic gels market is estimated to reach a valuation of US$ 1 Bn in 2022, with sales projected to grow at a 6.8% CAGR over the forecast period. Against this backdrop, the market size will surpass US$ 1.9 Bn by 2032.

Increasing adoption of hemostatic gels during surgical procedures for blood loss management is spurring demand for effective hemostatic gels. Furthermore, rising prevalence of chronic diseases is necessitating the adoption of these gels. According to the Centers for Disease Control and Prevention (CDC), more than 45% of the population in the U.S. suffers from at least one chronic disease that requires surgical procedures.

Globally, around 2,000,000 people die from hemorrhage each year, out of which approximately 1,500,000 deaths are due to trauma injuries. Similarly, every year almost 60,000 people die in the U.S. due to hemorrhaging and blood loss. These figures indicate the need for hemostatic gels during surgical procedures to improve clinical outcomes.

Ask for Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15085

Key Takeaways:

• Based on product type, sales of porcine-based hemostatic gels are expected to grow at a 5.7% CAGR through 2032.
• In terms of indication, the cardiovascular surgery segment is expected to account for 33.1% of the total market share over the assessment period.
• By end user, demand for hemostatic gels across hospitals will increase at a 5.4% CAGR during the forecast period.
• The U.S. dominated the North America hemostatic gels market in 2021, holding 82% of the total market share.
• Demand for hemostatic gels in India is forecast to grow at a 7.4% CAGR over the assessment period.
• Sales in the U.K. hemostatic gels market are expected to increase at a 7.1% CAGR through 2032.
• China will emerge as a lucrative pocket, with demand growing at an 8% CAGR over the forecast period.

“Rising adoption of effective hemostatic gels across various industries for the protection of the workforce is expected to fuel demand in the market. In addition to this, rising awareness regarding the usage of hemostatic gels for blood loss management across emerging economies will augment the growth in the market,” says an FMI analyst

Ask Our Analyst More about Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-15085

Competition Landscape

Key players operating in the hemostatic gels market are adopting strategies such as product launches, mergers & acquisitions, joint ventures, and R&D activities to improve their global presence. For instance:

• In 2019, Baxter International, Inc. introduced Floseal Hemostatic Matrix, its new hemostatic agent. Floseal Hemostatic Matrix U.S.FDA approved and is used to stop bleeding during surgical procedures.
• In 2021, Medcura, Inc. together with ASO LLC launched Rapid-Seal, a new class of antibacterial hemostatic gel. This product meets the market demand for a transparent gel that will be easily applied during surgeries.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the hemostatic gels market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

Key Market Segments Covered In Hemostatic Gels Industry Research

By Material:

• Bovine-Based
• Porcine-Based
• Polymer-Based

By Indication:

• General Surgery
• Dental Surgery
• Veterinary Surgery
• Cardiovascular Surgery
• Orthopaedic Surgery
• Others

By End-User:

• Hospitals
• Speciality Clinics
• Veterinary Settings
• Ambulatory Surgical Centers
• Online Sales

Request for Report Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-15085

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Development and Innovation Trends

4. Key Success Factors

Full TOC click Here

[324 Pages Report] During the forecast period, the paediatric spasticity treatment market is expected to grow at a CAGR of 10%. Rising demand for combination products such as benzodiazepines, imidazole, and gamma-aminobutyric acid analogues is driving the global paediatric spasticity treatment market. Furthermore, demand for paediatric spasticity treatment is increasing as a result of increased awareness and investment in research and development.

Paediatric Spasticity Treatment: Market Insights

Paediatric Spasticity results due to damage of portion of brain or spinal cord which controls the voluntary movement. When paediatric spasticity occurs due to injury or disease, nerve signals do not reach muscles and continuously contract which causes stiffness and tightness which interfere with movement and speech. Several drugs are available to treat the Paediatric Spasticity, drugs are injected into the affected nerve or the muscle.

Physical therapy used to increase strength, improve muscle mobility and muscle coordination, use of braces, and electrical stimulation. Oral medication for treatment of paediatric spasticity is considered when spasticity symptoms gets adverse and start affecting daily muscle functioning. According to estimates from CDC’s Autism and Developmental Disabilities Monitoring (ADDM) Network, about 1 in 323 children has been identified with Cerebral Palsy and most (77.4%) of the children identified with CP had spastic CP. 

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-9408 

Paediatric Spasticity Treatment: Market DynamicsIncreasing awareness, growing research and development for drug development drive the market of paediatric spasticity treatment in the near future. Changing lifestyle, developing new and innovative technology, improving healthcare infrastructure is expected to fuel the paediatric spasticity treatment market in the forecast period. Launch of novel therapeutics and growing per capita income in the emerging economies such as China, Brazil is further drive the paediatric spasticity treatment market.Despite many factors which drive the global market for paediatric spasticity treatment, various factor which might hinder the growth of paediatric spasticity treatment market include high cost of treatment and low awareness in under developed and developing countries and rigorous regulations for the approval of drug. 

Paediatric Spasticity Treatment: Overview

Advancement and development of new therapeutic treatment and growing clinical trials for the paediatric spasticity treatment creates huge opportunity for the paediatric spasticity treatment market to grow in the forecast period. Collaboration and partnership among major players for developing new drugs, increasing funding for the research will drive the market of paediatric spasticity treatment in near future. For instance, in august 2016, FDA Approved Ipsen’s Dysport (abobotulinumtoxina) injection for the treatment of lower limb spasticity in children aged two and older.

Paediatric Spasticity Treatment: Region-wise Outlook

The North America is expected to contribute to a major share in the global paediatric spasticity treatment, owing to increasing population, increasing number of screening procedures, presence of major manufacturers and growing clinical trials. Well-developed healthcare facilities and government funding for drug development further drive the market for paediatric spasticity treatment. Europe contributes for the second largest share with significant growth in the global paediatric spasticity treatment market owing to technological advancement in the treatment coupled with growing adoption of new treatment.

Asia Pacific market is primarily driven by the factors such as growing prevalence, increasing population, growing awareness of new treatment options. China is expected to register rapid growth in the paediatric spasticity treatment market, due to large patient pool, availability of new drugs for the paediatric spasticity treatment. Latin America and Middle East & Africa are projected to show sluggish growth in paediatric spasticity treatment market, due to less awareness, lack of adequate healthcare facilities and less developed infrastructure.

Pediatric Spasticity Treatment: Key Players

Some of the key players present in the global pediatric spasticity treatment market are Allergan plc, Ipsen Biopharmaceuticals, Inc., Almirall, S.A, Piramal Critical Care, Inc., Genentech, Inc, Sanofi, Saol Therapeutics, US WorldMeds, LLC among others.

The report covers exhaustive analysis on,

• Pediatric Spasticity Treatment Market Segments
• Pediatric Spasticity Treatment Market Dynamics
• Historical Actual Market Size, 2012 – 2016
• Pediatric Spasticity Treatment Market Size & Forecast 2016 to 2024
• Pediatric Spasticity Treatment Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Pediatric Spasticity Treatment Market Drivers and Restraints

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-9408

Regional analysis includes

• North America
• Latin America
• Europe
• Asia Pacific Excluding China
• China
• Middle East & Africa

Pediatric Spasticity Treatment: Segmentation 

The global Pediatric Spasticity Treatment market is segmented on basis of drug type, distribution channel and geography.

Segmentation by Drug Type

• Baclofen or Muscle Relaxants
• Botox
• Intrathecal Baclofen
• Clonazepam
• Diazepam
• Tizanidine
• Others

Segmentation by Route Of Administration

• Oral
• Injectable

Segmentation by Distribution Channel

• Hospitals Pharmacies
• Drug Stores
• Retail Pharmacies
• Mail Order Pharmacies

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[250 Pages Report] The Medical Billing Outsourcing Market revenues were estimated at US$ 11.1 Bn in 2021 and is anticipated to grow at a CAGR of 16% from 2022-2032, according to a recently published Future Market Insights report. By the end of 2032, the market is expected to reach a valuation of US$ 55.6 Bn.

The covid-19 epidemic has had a positive impact on the growth of the medical billing outsourcing industry. It is due to the expanding influence of technology in the healthcare business, which has traditionally relied on localized healthcare systems. The pandemic has accelerated market growth by accelerating digital development in a variety of industries, including healthcare.

The pandemic has highlighted the significance of adopting proactive actions and establishing a strong, extendable, collaborative, and reactive digital healthcare infrastructure. As a result, in order to enhance market development, numerous organizations are adopting methods such as digitization and outsourcing of all non-core areas of their operations, such as invoicing and accounting. The rapid move to digital billing is directly related to the growing demand for the medical billing outsourcing market.

Key Takeaways from the Market Study

• Medical Billing Outsourcing Market was valued at US$ 11.1 Bn in 2021. According to Future Market Insights, Medical Billing Outsourcing Market revenue would increase 4.4X between 2022 and 2032, reaching roughly US$ 55.6 Bn in 2032.
• In terms of Component, the Outsourced segment accounts for the highest projected CAGR of over 15.6%.
• In terms of End-Use, the Hospital accounts for the highest projected CAGR of over 17.1%.
• US is the dominant region in the Medical Billing Outsourcing Market with an expected absolute dollar growth opportunity of US$ 18.4 Bn during 2022 – 2032.

“During the projected period, the rise in the number of hospitals in terms of end-use can become a key driver towards raising the medical billing outsourcing market revenue.” comments a Future Market Insights analyst.

Request Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-15082

Competitive Landscape

The medical billing outsourcing market is very competitive, with numerous medium, and small businesses fighting against one another. Mergers, partnerships, and acquisitions are some of the key business methods used by corporations to increase their market share.

Some of the key medical billing outsourcing service providers include R1 RCM Inc., Cerner Corporation, Allscripts Healthcare Solutions Inc., Experian Information Solutions Inc., eClinicalWorks LLC, Athenahealth, Quest Diagnostics, Promantra Inc., AdvancedMD, Inc., Kareo, Inc., and McKesson Corporation.

Some of the key developments in the global medical billing outsourcing industry are:

• In March 2022, Omega Healthcare, a prominent healthcare management services and solution firm, acquired Reventics, a revenue cycle management solution developer which delivers provider engagement solutions to increase physician reimbursement & compliance.
• In July, 2021, R1 RCM Inc., a supplier of technology-driven solutions that enhance healthcare providers’ patient experiences and financial performance, announced the completion of its purchase of VisitPay, a digital payment solution provider. The purchase integrates VisitPay’s customer payments infrastructure with R1’s leading patient access technology, allowing providers to offer their patients a smooth financial journey

Market Segments Covered In Medical Billing Outsourcing Market Analysis

By Component:

• In-house Medical Billing
• Outsourced Medical Billing

By Service Type:

• Front End
• Middle End
• Back End

By End-use:

• Hospital
• Physician Office
• Other End-uses

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-15082

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Medical Billing Outsourcing Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals extensive growth in Medical Billing Outsourcing Market across in terms of Component (In-house, Outsourced), Service Type (Front End, Middle End, Back End), End-Use (Hospital, Physician Office, Other End-uses) across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

[250 Pages Report] The therapeutic drug monitoring market is anticipated to witness an opulent growth with a phenomenal CAGR of 9.7% during the forecast period, up from US$ 1.5 Billion in 2020 to reach a valuation of US$ 2.9 Billion by 2026.

[250 Pages Report] The global protein crystallization and crystallography market is estimated to reach US$ 2.23 billion in 2028. Proteins are the organic macromolecules that are composed of long chain of amino acids. Protein crystallization and crystallography is the process for the formation of small protein crystals. This process is widely used by industrial and scientific purposes. Proteins normally functions in aqueous environments thus protein crystallization process is generally carried out in water.

The main goal behind protein crystallization and crystallography is to develop well ordered protein crystals that overcome the inherent fragility of protein molecules.  Many factors such as purity of proteins, concentration of proteins, pH, temperature of medium, additives (buffers) and precipitation (such as ammonium sulfate and polyethylene glycol) may influence the process of protein crystallization and crystallography.

The major factor influencing the market growth of protein crystallization and crystallography market is the development of new technologies. The factor enables to develop new area of advancements for this market and hence drives the growth of protein crystallization and crystallography market. In addition, increasing need for high resolution information on protein structures will further drive the growth of crystallization and crystallography market.

The other factor that stimulates the growth of crystallization and crystallography market includes increasing government grants and research and development activities in the biotechnological and pharmaceutical industries which demand the utilization of crystallization and crystallography techniques. Furthermore, emergence of advance technologies like X-ray-free electron lasers in protein crystallization and crystallography market increases the number of users and drives the market growth.

Request Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-425

However, lack of skilled and knowledgeable personnel to operate this technique will restrain the growth of this market. In addition, high cost and time consuming method further restrains the growth of protein crystallization and crystallography market. Moreover, protein crystallization method is limited to specific types of protein molecules that will also restrain the growth of protein crystallization and crystallography market.

Geographically, North America accounts for the largest market of protein crystallization and crystallography. Presence of large number of pharmaceutical and biotechnologies companies coupled with increasing research and development activities in North America will help this region to hold strong position in the market. Europe is considered as the second largest market for protein crystallization and crystallography.

The growth in Europe is mainly attributed to positive initiatives from European government coupled with increasing acceptance of protein crystallization and crystallography among people. In addition, Asia-Pacific countries such as India and China are the emerging regions for the global protein crystallization and crystallography market due to increasing investment by pharmaceutical and biotechnology companies in this region.

The major players competing in protein crystallization and crystallography market are Hampton Research, Molecular Dimensions Ltd., PerkinElmer, Inc., GE Healthcare Life Sciences, Danaher Corporation, Bruker Corporation, Agilent Technologies, Inc., Hampton Research, Jena Bioscience, Rigaku Corporation, Formulatrix, Inc., MiTeGen LLC, Bruker Corporation and others.

This research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data and statistically-supported and industry-validated market data and projections with a suitable set of assumptions and methodology. It provides analysis and information by categories such as market segments, regions, product types and distribution channels.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-425

Table of Content

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

1. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

1. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Product Life Cycle Analysis

3.5. Supply Chain Analysis

3.5.1. Supply Side Participants and their Roles

3.5.1.1. Producers

3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)

3.5.1.3. Wholesalers and Distributors

3.5.2. Value Added and Value Created at Node in the Supply Chain

3.5.3. List of Raw Material Suppliers

3.5.4. List of Existing and Potential Buyer’s

3.6. Investment Feasibility Matrix

3.7. Value Chain Analysis

3.7.1. Profit Margin Analysis

3.7.2. Wholesalers and Distributors

3.7.3. Retailers

3.8. PESTLE and Porter’s Analysis

3.9. Regulatory Landscape

3.9.1. By Key Regions

3.9.2. By Key Countries

3.10. Regional Parent Market Outlook

3.11. Production and Consumption Statistics

3.12. Import and Export Statistics

About FMI: